Summary & Overview
HCPCS C9449: Blinatumomab Injection, 1 mcg
HCPCS Level II code C9449 covers administration of blinatumomab measured per 1 mcg. Blinatumomab is an oncology therapeutic with significance for treatment pathways where precise dosing and billing granularity are required. Nationally, accurate representation of per-microgram billing supports appropriate claims processing, utilization tracking, and payment for high-cost biologic therapies.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical meaning and typical site of service, plus information useful for billing teams and revenue cycle stakeholders: national coverage context, coding relationships, and where to look for payer-specific policy variations. The publication highlights benchmarks and policy-relevant considerations affecting billing for monoclonal antibody infusions and similar oncology injectables.
This summary serves clinicians, billing professionals, and policy analysts seeking a national-level briefing on HCPCS Level II code C9449, what it represents clinically, and the payer landscape to consult for coverage and claim adjudication. Data not available in the input for specific modifiers, taxonomies, ICD-10 pairings, and payer-specific reimbursement rates.
Billing Code Overview
HCPCS Level II code C9449 represents Injection, blinatumomab, 1 mcg. The service type is therapeutic injection of a monoclonal bispecific T-cell engager used in oncology treatment. Typical site of service is infusion center or hospital outpatient setting, where intravenous or subcutaneous administration and monitoring occur.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric individual diagnosed with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) who is receiving targeted immunotherapy with blinatumomab. The patient presents to an outpatient oncology infusion center or hospital infusion unit for administration of continuous intravenous infusion of blinatumomab; dosing commonly requires microgram-level unit billing (C9449 is billed per 1 mcg). The clinical workflow includes pre-infusion evaluation (vital signs, neurologic and cytokine release syndrome screening), verification of medication order and dose calculation by pharmacy, placement of appropriate vascular access (peripheral IV or central venous catheter), initiation of continuous infusion pump, frequent monitoring during initial inpatient or outpatient observation period, documentation of infusion rate adjustments, and periodic neurologic assessments during therapy. Pharmacy compounds the drug under sterile conditions and labels infusion bags; nursing documents administration and any adverse reactions. Follow-up visits include laboratory monitoring (CBC, metabolic panel) and assessment of treatment response with bone marrow evaluation or peripheral blood counts as clinically indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure |